This is a Phase 2, multi-center, open label, randomized clinical study to evaluate the safety and efficiency of SDX-101 in combination with chlorambucil (CLB) and chlorambucil alone in Chronic Lymphocytic Leukaemia (CLL) patients. The study treatment period will be approximately 24-26 weeks with a follow-up period of approximately 8 weeks. Following the end of treatment, patients with a confirmed complete response, partial response or stable disease will be followed for up to 2 years to assess time to disease progression. A maximum of 80 evaluable patients with documented diagnosis of B-cell CLL by standard clinical and immunophenotyping criteria will be enrolled into the SDX-101-03 study. This study is being conducted in the following European countries: France, Germany, Poland, Sweden and the United Kingdom.

Condition	Intervention	Phase
Chronic Lymphocytic Leukemia	Drug: SDX-101 (R-etodolac)	Phase II

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

1. Diagnosis of B-cell CLL by standard clinical and immunophenotypic criteria as specified by the NCI working group revised guidelines for diagnosis and treatment of CLL(32).

2. Binet stages A-C with evidence of active disease requiring treatment by the presence of one or more of the following at the time of study entry:

   • Disease related B symptoms (Fever > 38C [100.5F] for ≥ 2 weeks without evidence of infection, night sweats without evidence of infection, weight loss > 10% within previous 6 mo.).

   • Evidence of progressive marrow failure as manifested by: • A decrease in hemoglobin to < 10g/dL, or • A decrease in platelet count to < 100 x 10(9)/L within the previous 6 months, or • A decrease in absolute neutrophil count (ANC) to < 1.0 x 10(9)/L within 6 months • Progressive lymphocytosis with an increase of > 50% over a 2 month period, or an anticipated doubling time of < 6 months.

   • Massive nodes or clusters(i.e., > 10 cm in longest diameter) or progressive lymphadenopathy.

   • Progressive splenomegaly to > 2cm below the left costal margin or other organomegaly with progressive increase over 2 consecutive clinical visits ≥ 2 weeks apart.

3. No prior chemotherapy for CLL.
4. Age ≥ 18 at signing of informed consent.
5. World Health Organization (WHO) performance status ≤ 0-2 (Appendix B).
6. Platelet count > 50,000/μL, hemoglobin > 8.0 g/dl and absolute neutrophil count > 1000/μL.
7. Renal function ≤ 1.5 x upper limit normal (blood urea nitrogen [BUN], serum creatinine)
8. Liver function ≤ 1.5 times upper limit of normal (total bilirubin, SGOT (AST) and SGPT (ALT) values).
9. Female patients of childbearing potential must have a negative pregnancy test (serum or urine Beta-human chorionic gonadotropin, Beta-HCG); men and women of reproductive potential must employ effective contraceptive methods while on study therapy, and for 2 months following completion of treatment.
10. Signed EC/IRB-approved informed consent by patient prior to all study related procedures.

Exclusion Criteria:

1. Active autoimmune manifestation of CLL such as ongoing hemolytic anemia or ITP
2. History of a second malignancy with the exception of cervical cancer,or resected basal cell carcinoma or other malignancies with no evidence of recurrence 5 or more years since diagnosis.
3. Chronic viral infection: positive hepatitis B or hepatitis C serology, known positive for human immunodeficiency virus (HIV) or human T-leukemia/lymphoma virus (HTLV).
4. Transformation to an aggressive B-cell malignancy such as Richter’s transformation, prolymphocytic leukemia (PLL) or large B-cell lymphoma.
5. Clinical evidence of CNS involvement with CLL.
6. Serious infection, medical condition, or psychiatric condition that, in the opinion of the investigator, might interfere with the achievement of the study objectives.
7. Treatment with any investigational agent within 4 weeks of study entry.
8. The use of steroids, nonsteriodal anti-inflammatory drugs, regardless of indication (excluding prophylactic use of aspirin for prevention of acute myocardial infarction or stroke)
9. Pregnancy or currently breast feeding.

Please refer to this study by ClinicalTrials.gov identifier  NCT00151736

France
      Chef du Service d’Hematologie Clinique CHU Clemenceau, Caen,  France; Recruiting
      Service maladies du sang CHRU- rue Michel Polonovski, Lille,  France; Recruiting
Germany
      Medizinische Poliklinik der Universität Hämatologie/Onkologie, Würzburg,  Germany; Recruiting
      Charité - Benjamin Franklin Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin, Berlin,  Germany; Recruiting
      Internistische Schwerpunktpraxis, Erlangen,  Germany; Recruiting
Poland
      Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Klinika Hematologii Instytutu Medycyny Wewnetrznej Uniwersytetu Medycznego w Lodzi, Lodz,  Poland; Recruiting
      Uniwersytet Jagiellonski Collegium Medicum Katedra i Klinika Hematologii, Krakow,  Poland; Recruiting
      Samodzielny Publiczny Szpital Kliniczny Nr 1 Akademickie Centrum Kliniczne Akdemii Medycznej w Gdansku Klinika Hematologii, Gdansk,  Poland; Recruiting
      Samodzielny Publiczny Centralny Szpital Kliniczny Katedra i Klinika Hematologii Onkologii i Chorob Wewnetrznych AM, Warszawa,  Poland; Recruiting
      Prywatna Praktyka Lekarska z Osrodkiem Badan Klinicznych Prof. L. Szczepanskiego, Lublin,  Poland; Recruiting
      Samodzielny Publiczny Szpital Kliniczny Nr 1 Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw,  Poland; Recruiting
      Samodzielny Publiczny Szpital Kliniczny AM Klinika Hematologii, Bialystok,  Poland; Recruiting
Sweden
      Hematologkliniken Karolinska Universitetssjukhuset, Huddinge, Stockholm,  Sweden; Recruiting
      Centrum för Hematologi Karolinska Universitetssjukhuset, Solna, Stockholm,  Sweden; Recruiting
      Hematologisektionen Medicincentrum Akademiska sjukhuset, Uppsala,  Sweden; Recruiting
      Hematologkliniken Norrlands Universitetssjukhus, Umeå,  Sweden; Recruiting
United Kingdom
      Stobhill Hospital Department of Haematology, Glasgow,  United Kingdom; Recruiting
      Royal Bournemouth Hospital Dept. of Haematology, Bournemouth,  United Kingdom; Recruiting
      Leicester Royal Infirmary Department of Oncology & Haematology, Leicester,  United Kingdom; Recruiting
      Leeds General Infirmary Department of Haematology, Leeds,  United Kingdom; Recruiting
      Nottingham City Hospital NHS Trust, Nottingham,  United Kingdom; Recruiting
      Cardiff and Vale NHS Trust University Hospital of Wales, Cardiff,  United Kingdom; Recruiting

Study ID Numbers:  SDX-101-03
Last Updated:  September 8, 2005
Record first received:  September 7, 2005
ClinicalTrials.gov Identifier:  NCT00151736
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13